New Biomarker Study of Rapid-Acting Treatment for Acute Depression


Apimostinel is in development for the treatment of acute depressive disorders and depression with suicidality.

Anantha Shekhar, MD, PhD, discusses Gate Neuroscience's phase 1 study of rapid-acting antidepressant, apimostinel.

You can read more about apimostinel in "Phase 1 Study of Apimostinel for Depression Doses First Participants."

Dr Shekhar is senior vice chancellor for the health sciences and John and Gertrude Petersen Dean of the School of Medicine at the University of Pittsburgh. He is also a professor of psychiatry and a professor of clinical and translational science, as well as Chief Scientific Officer of Gate Neuroscience.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
© 2024 MJH Life Sciences

All rights reserved.